Clinical Trial Update: BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dasatinib (BMS-354825) in patients with chronic phase chronic myeloid leukemia who did not respond to prior imatinib therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)
• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Leukemia | Phase 2 | Status: UNKNOWN